PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) reported notable progress in Q1 2025, emphasizing advancements in its clinical and preclinical iPSC-derived cell therapy programs. Highlights include updates on the CALiPSO-1 trial for CNTY-101, plans for IND-enabling studies for CNTY-308, and data presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.
Patient dosing has begun in the Phase 1 CALiPSO-1 trial, which is evaluating CNTY-101 for B-cell-mediated autoimmune diseases. The trial is active at five U.S. clinical sites, with plans to expand across additional U.S. and European sites. Regulatory approvals have been secured in Germany, France, and Italy. Additionally, the CARAMEL investigator-initiated trial in Germany is expected to start by mid-2025, further expanding research on CNTY-101. Clinical data from the CALiPSO-1 trial is anticipated by the end of 2025.
On the preclinical front, Century plans to initiate IND-enabling studies for CNTY-308, its CD19-targeted CD4+/CD8+ CAR-iT cell therapy, by mid-2025. The therapy leverages the company’s Allo-Evasion™ 5.0 technology, designed to provide resistance against immune rejection. The company is also advancing pipelines for solid tumor therapies and engineering non-immune effector cells for high-impact diseases.
At ASGCT, Century presented data showcasing its innovative iPSC-based approaches, including scalable, tunable CD4+/CD8+ CAR-T cells and enhanced immunotherapies capable of overcoming the solid tumor microenvironment.
“We have made significant strides advancing our clinical and preclinical pipeline while leveraging our iPSC platform to develop scalable, accessible cell therapies,” said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics. “With patient dosing underway for CNTY-101 and IND-enabling studies for CNTY-308 on the horizon, we are poised to drive significant progress in cell therapy innovation. Our disciplined approach ensures we remain focused on bringing transformational therapies to patients.”
Financially, Century reported $185.8 million in cash and equivalents at quarter-end, which is expected to fund operations into Q4 2026. Revenue rose significantly to $109.2 million due to recognition of collaboration funds following the termination of its agreement with Bristol-Myers Squibb. Research and development expenses increased to $26.6 million, attributed to clinical trial costs and preclinical advancements.
Century Therapeutics is strategically positioned to revolutionize cell therapy development with its innovative iPSC-derived platforms, offering the potential for robust solutions in autoimmune diseases, cancer, and other critical areas of unmet need.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.